1052714-13-2

Basic information

• Product Name: methyl 3-amino-6-bromo-5-fluoropicolinate
• Synonyms: methyl 3-amino-6-bromo-5-fluoropicolinate
• CAS NO: 1052714-13-2
• Molecular Formula: C7H6BrFN2O2
• Molecular Weight: 249.039
• Mol File: 1052714-13-2.mol

Chemical Properties

• Boiling Point: 340.5±37.0 °C(Predicted)
• Density: 1.738±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl 3-amino-6-bromo-5-fluoropicolinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-amino-6-bromo-5-fluoropicolinate(1052714-13-2)
• EPA Substance Registry System: methyl 3-amino-6-bromo-5-fluoropicolinate(1052714-13-2)

Safety Data

• Hazardous Substances Data: 1052714-13-2(Hazardous Substances Data)

Upstream product

• 1033202-51-5 5-fluoro-3-nitropyridine-2-carbonitrile 
• 1052714-11-0 3-amino-5-fluoropyridine-2-carboxylic acid methyl ester 
• 884495-03-8 3-amino-2-bromo-5-fluoropyridine 

Downstream Products

• 1620013-06-0 C₃₀H₃₃F₃N₆O₄ 
• 1620011-34-8 3-amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-2,3-dihydrofuro[2,3-b]pyridin-5-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide 
• 1620011-83-7 3-({[3-amino-6-(2,6-difluorophenyl)-5-fluoropyridin-2-yl]carbonyl}amino)-4-{(3S)-3-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate 
• 1620011-82-6 3-amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide 
• 1052714-18-7 3-amino-6-(2,6-difluorophenyl)-5-fluoro-2-pyridinecarboxylicacidmethylester 

Relevant articles and documents

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES

Therapeutic combinations of hepatitis B virus (HBV) vaccines and a pyridopyrimidine derivative are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

Pyridine derivative PIM kinase inhibitor and preparation method therefor and application thereof in pharmacy

The present invention provides a PIM kinase inhibitor and a preparation method therefor and an application thereof. The PIM kinase inhibitor is a compound with the structural formula shown in the formula I (the formula is shown in description). The present invention further provides a stereoisomer, a tautomer and pharmaceutical salt of the compound shown in the formula I. According to the present invention, the compound has an obvious inhibition effect on kinase activity. The PIM kinase inhibitor can be used for preparing drugs for curing or preventing cancer, autoimmune diseases, allergic reaction diseases or organ transplant rejection resistance and the like, and the PIM kinase inhibitor has relatively large value in clinical application.

TOLL LIKE RECEPTOR MODULATOR COMPOUNDS

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

SUBSTITUTED PYRIDINES AND METHOD OF USE

The invention discloses compounds of Formula (I) wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.